XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenue recognition and accounts receivable | 6 Months Ended
--- | ---
Jun. 30, 2019
Revenue Recognition And Accounts Receivable [Abstract] |
Revenue recognition and accounts receivable | 11. Revenue recognition and accounts receivable Revenue Recognition The Company has two reporting segments, which consist of Global Spine and Global Extremities. Within the Global Spine reporting segment there are three product categories: Bone Growth Therapies, Spinal Implants and Biologics. The tables below present net sales by major product category by reporting segment:
|  | Three Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Bone Growth Therapies |  | $ | 50,109 |  |  | $ | 48,211 |  |  |  | 3.9 | %
Spinal Implants |  |  | 23,226 |  |  |  | 23,880 |  |  |  | -2.7 | %
Biologics |  |  | 16,744 |  |  |  | 14,668 |  |  |  | 14.2 | %
Global Spine |  |  | 90,079 |  |  |  | 86,759 |  |  |  | 3.8 | %
Global Extremities |  |  | 25,771 |  |  |  | 24,788 |  |  |  | 4.0 | %
Net sales |  | $ | 115,850 |  |  | $ | 111,547 |  |  |  | 3.9 | %
|  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Bone Growth Therapies |  | $ | 97,392 |  |  | $ | 94,374 |  |  |  | 3.2 | %
Spinal Implants |  |  | 46,129 |  |  |  | 44,587 |  |  |  | 3.5 | %
Biologics |  |  | 32,476 |  |  |  | 29,003 |  |  |  | 12.0 | %
Global Spine |  |  | 175,997 |  |  |  | 167,964 |  |  |  | 4.8 | %
Global Extremities |  |  | 48,965 |  |  |  | 52,292 |  |  |  | -6.4 | %
Net sales |  | $ | 224,962 |  |  | $ | 220,256 |  |  |  | 2.1 | %
Product Sales and Marketing Service Fees The table below presents net sales, which includes product sales and marketing service fees, for the three and six months ended June 30, 2019 and 2018.
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Product sales |  | $ | 99,865 |  |  | $ | 97,453 |  |  | $ | 193,799 |  |  | $ | 192,342 |
Marketing service fees |  |  | 15,985 |  |  |  | 14,094 |  |  |  | 31,163 |  |  |  | 27,914 |
Net sales |  | $ | 115,850 |  |  | $ | 111,547 |  |  | $ | 224,962 |  |  | $ | 220,256 |
Product sales primarily consist of the sale of bone growth therapy devices and internal and external fixation products. Marketing service fees are received from MTF Biologics based on total sales of biologics tissues and relate solely to the Global Spine r eporting segment. Revenues exclude any value added or other local taxes, intercompany sales and trade discounts. Shipping and handling costs for products shipped to customers are included in cost of sales. Puerto Rico Settlement In June 2019, the Company received a payment of $1.4 million from the Administration of Medical Services of Puerto Rico, a government-owned corporation, in settlement of approximately $2.5 million of outstanding accounts receivable. This $2.5 million of outstanding accounts receivable had previously been fully reserved between the Company’s allowances for doubtful accounts and contractual allowances. As a result of this settlement, and in accordance with the Company’s policy, the Company recorded the resulting adjustment to contractual allowances of $0.4 million within net sales and the recovery of the allowance for doubtful accounts as a credit to bad debt expense of $1.0 million. Other Contract Assets The Company’s contract assets, excluding trade accounts receivable (“other contract assets”), largely consist of payments made to certain distributors to obtain contracts, gain access to customers in certain territories, and to provide the benefit of the exclusive distribution of Orthofix products. Other contract assets are included in other long-term assets or other current assets, dependent upon the original term of the related agreement, and totaled $3.9 million and $1.9 million as of June 30, 2019, and December 31, 2018, respectively.

X
- Definition Revenue recognition and accounts receivable. + References No definition available. + Details
Name: | ofix_RevenueRecognitionAndAccountsReceivableAbstract
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration